News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 03, 2010
Porton Down, UK, 3 December 2010: GW Pharmaceuticals (AIM: GWP) today announces that it has appointed Peel Hunt Limited as Nominated Adviser and broker to the Company with immediate effect.
Nov 23, 2010
Porton Down, UK; 23 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces the initiation of the Phase III clinical trials programme of Sativex® in the treatment of pain in patients with a
Nov 23, 2010
Porton Down, UK, 23 November 2010: GW Pharmaceuticals plc (AIM: GWP), the specialty pharmaceutical company focused on cannabinoid science, announces its preliminary results for the year ended 30 Sep
Nov 03, 2010
Porton Down, UK, 3 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces that the New Zealand regulatory authority, MedSafe, has approved Sativex® as a treatment for the relief of spastic
Oct 21, 2010
Porton Down, UK, 21 October 2010: GW Pharmaceuticals plc (AIM: GWP) will be announcing its preliminary financial results for the year end 30 September 2010 on Tuesday 23 November 2010.
Oct 14, 2010
Porton Down, UK, 14 October 2010: GW Pharmaceuticals plc (AIM: GWP) is pleased to note today’s announcement from marketing partner, Almirall, S.A., that efficacy data from three Phase III trials of
Sep 30, 2010
Porton Down, UK, 30 September 2010: GW Pharmaceuticals plc (GWP:AIM) announces that it has commenced the first of a programme of Phase IIa exploratory clinical trials exploring GW’s cannabinoids as
Sep 22, 2010
Porton Down, UK, 22 September 2010: GW Pharmaceuticals plc (GWP:AIM) announces that results of a Phase II clinical study of Sativex® (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) in the
Aug 31, 2010
Porton Down, UK; Toronto, Canada – August 31, 2010 – GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announced that Health Canada has approved Sativex® [delta-9-tet

Pages